Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Ralpha1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD).
Purity:
>99.0%
CAS Number:
[2445460-16-0]
* VAT and and shipping costs not included. Errors and price changes excepted